RVTY – Revvity Inc

RVTY — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

5.87

Margin Of Safety %

Put/Call OI Ratio

0.85

EPS Next Q Diff

-0.12

EPS Last/This Y

0.38

EPS This/Next Y

0.52

Price

154.47

Target Price

174.57

Analyst Recom

2.55

Performance Q

33.01

Upside

-67.8%

Beta

1.09

Ticker: RVTY

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-15	RVTY	154.65	0.68	0.52	7999
2026-10-16	RVTY	152.63	0.68	28.33	8008
2026-10-19	RVTY	150.84	0.59	0.01	6575
2026-10-20	RVTY	156.04	0.50	0.53	7357
2026-10-21	RVTY	156.65	0.50	0.16	7411
2026-10-22	RVTY	157.38	0.50	0.33	7421
2026-10-23	RVTY	158.73	0.50	2.17	7475
2026-10-26	RVTY	160.31	0.50	0.16	7474
2026-10-27	RVTY	161.8	0.48	2.13	7690
2026-10-28	RVTY	165.34	0.49	6.34	7749
2026-10-29	RVTY	165.71	0.59	0.07	8330
2026-10-30	RVTY	157	0.60	0.08	8350
2026-11-02	RVTY	151.65	0.62	1.75	8246
2026-11-03	RVTY	163.64	0.89	13.74	12313
2026-11-04	RVTY	159.41	0.82	2.33	12065
2026-11-05	RVTY	150.86	0.82	2.63	12107
2026-11-06	RVTY	155.22	0.83	0.13	12134
2026-11-09	RVTY	160.8	0.83	3.40	12122
2026-11-10	RVTY	159.24	0.83	0.59	12122
2026-11-11	RVTY	158.29	0.84	0.84	12654
2026-11-12	RVTY	157.02	0.84	0.28	12657
2026-11-13	RVTY	154.47	0.85	0.83	12777
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-15	RVTY	154.71	9.9	379.9	5.35
2026-10-16	RVTY	152.62	9.9	371.9	5.35
2026-10-19	RVTY	150.85	9.9	365.1	5.35
2026-10-20	RVTY	150.85	9.9	365.1	5.35
2026-10-21	RVTY	156.03	9.9	385.0	5.35
2026-10-22	RVTY	157.33	9.9	390.0	5.35
2026-10-23	RVTY	158.70	9.9	392.5	5.35
2026-10-26	RVTY	160.34	9.9	401.6	5.35
2026-10-27	RVTY	161.85	9.9	407.4	5.35
2026-10-28	RVTY	165.32	9.9	420.8	5.35
2026-10-29	RVTY	165.71	9.9	422.3	5.35
2026-10-30	RVTY	157.00	9.9	388.7	5.35
2026-11-02	RVTY	151.70	9.9	368.3	5.35
2026-11-03	RVTY	163.64	9.9	414.3	5.35
2026-11-04	RVTY	159.44	9.9	-	5.35
2026-11-05	RVTY	150.84	9.9	-	5.35
2026-11-06	RVTY	155.16	-5.0	-	5.35
2026-11-09	RVTY	160.74	-5.8	121.7	5.35
2026-11-10	RVTY	159.18	-4.8	102.1	5.44
2026-11-11	RVTY	158.22	-4.8	103.8	5.44
2026-11-12	RVTY	157.02	-4.8	102.9	5.44
2026-11-13	RVTY	154.47	-4.8	99.2	5.44
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-15	RVTY	-1.73	6.20	5.67
2026-10-16	RVTY	-1.73	6.20	5.67
2026-10-19	RVTY	-1.73	6.19	5.67
2026-10-20	RVTY	-1.73	6.19	5.67
2026-10-21	RVTY	-1.73	6.19	5.67
2026-10-22	RVTY	-1.73	6.19	5.67
2026-10-23	RVTY	-1.71	6.19	5.67
2026-10-26	RVTY	-1.71	6.20	5.67
2026-10-27	RVTY	-1.71	6.20	5.76
2026-10-28	RVTY	-1.71	6.20	5.76
2026-10-29	RVTY	-1.71	6.20	5.76
2026-10-30	RVTY	-1.71	6.20	5.76
2026-11-02	RVTY	-1.71	6.45	5.76
2026-11-03	RVTY	-1.71	6.45	5.76
2026-11-05	RVTY	-1.71	6.45	5.76
2026-11-06	RVTY	-1.71	6.45	5.76
2026-11-09	RVTY	-1.71	4.64	5.76
2026-11-10	RVTY	-1.71	4.64	5.76
2026-11-11	RVTY	-1.71	4.64	5.88
2026-11-12	RVTY	-1.71	4.64	5.88
2026-11-13	RVTY	-1.71	4.64	5.87
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

1.38

Avg. EPS Est. Current Quarter

1.62

Avg. EPS Est. Next Quarter

1.26

Insider Transactions

-1.71

Institutional Transactions

4.64

Beta

1.09

Average Sales Estimate Current Quarter

761

Average Sales Estimate Next Quarter

723

Fair Value

168.67

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-59

Target Price

174.57

P/E

68.49

Forward P/E

25.93

PEG

2.91

P/S

5.86

P/B

2.37

P/Free Cash Flow

29.21

EPS

2.26

Average EPS Est. Cur. Y

5.44

EPS Next Y. (Est.)

5.96

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

8.61

Relative Volume

0.69

Return on Equity vs Sector %

-22.9

Return on Equity vs Industry %

-7.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.08

EBIT Estimation

99.2

◆ RVTY Healthcare

$154.52

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

2/20

Pullback

23/25

Volume

6/15

Valuation

15/20

TP/AR

2/10

Options

2/10

RSI

Range 1M

29.7%

Sup Dist

0.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

10/30

Estimates

6/20

Inst/Vol

8/15

Options

3/10

EPS Yr

7.2%

EPS NY

9.9%

52W%

82.2%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -2.2% upside

Quality

8/30

Valuation

4/30

Growth

10/25

Stability

9/10

LT Trend

1/5

Upside

-2.2%

Quality

MoS

RVTY — P/E HistoricalDiagnostics & Research

Revvity, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 11000

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

RVTY

Latest News

—

Caricamento notizie per RVTY…

stock quote shares RVTY – Revvity Inc Stock Price stock today

news today RVTY – Revvity Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch RVTY – Revvity Inc yahoo finance google finance

stock history RVTY – Revvity Inc invest stock market

stock prices RVTY premarket after hours

ticker RVTY fair value insiders trading

XGN – Exagen Inc.

XGN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

4.8

Margin Of Safety %

Put/Call OI Ratio

0.42

EPS Next Q Diff

0.08

EPS Last/This Y

0.2

EPS This/Next Y

0.23

Price

4.14

Target Price

9.43

Analyst Recom

Performance Q

-38.36

Upside

-735.6%

Beta

2.27

Ticker: XGN

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-15	XGN	8.54	0.19	999.99	563
2026-10-16	XGN	7.75	0.19	0.00	551
2026-10-19	XGN	7.45	0.34	999.99	328
2026-10-20	XGN	7.38	0.44	6.60	353
2026-10-21	XGN	7.83	0.44	6.60	353
2026-10-22	XGN	7.49	0.44	6.60	353
2026-10-23	XGN	7.29	0.56	999.99	389
2026-10-26	XGN	7.47	0.56	0.40	389
2026-10-27	XGN	7.81	0.53	999.99	459
2026-10-28	XGN	8.4	0.53	999.99	459
2026-10-29	XGN	8.71	0.47	0.00	440
2026-10-30	XGN	8.57	0.47	0.00	440
2026-11-02	XGN	8.39	0.47	0.00	440
2026-11-03	XGN	8.31	0.46	0.00	445
2026-11-04	XGN	8.53	0.46	999.99	445
2026-11-05	XGN	7.59	0.46	999.99	447
2026-11-06	XGN	5.75	0.46	1.94	448
2026-11-09	XGN	7.1	0.51	0.00	448
2026-11-10	XGN	5.26	0.48	0.08	470
2026-11-11	XGN	5.03	0.51	20.00	457
2026-11-12	XGN	4.41	0.42	0.33	433
2026-11-13	XGN	4.12	0.42	0.00	437
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-15	XGN	8.54	45.2	-	-0.62
2026-10-16	XGN	7.74	45.2	-	-0.63
2026-10-19	XGN	7.44	45.2	-	-0.63
2026-10-20	XGN	7.44	45.2	-	-0.63
2026-10-21	XGN	7.38	45.2	-	-0.63
2026-10-22	XGN	7.49	45.2	-	-0.63
2026-10-23	XGN	7.29	45.2	-	-0.63
2026-10-26	XGN	7.47	45.2	-	-0.63
2026-10-27	XGN	7.80	45.2	-	-0.63
2026-10-28	XGN	8.39	45.2	-	-0.63
2026-10-29	XGN	8.69	45.2	-	-0.63
2026-10-30	XGN	8.59	45.2	-	-0.63
2026-11-02	XGN	8.38	45.2	-	-0.63
2026-11-03	XGN	8.32	45.2	-	-0.63
2026-11-04	XGN	8.53	45.2	-	-0.63
2026-11-05	XGN	7.59	45.2	-	-0.63
2026-11-06	XGN	5.82	45.2	-	-0.65
2026-11-09	XGN	7.10	45.2	-	-0.65
2026-11-10	XGN	5.26	45.2	-	-0.65
2026-11-11	XGN	5.03	45.2	-	-0.65
2026-11-12	XGN	4.41	45.2	-	-0.65
2026-11-13	XGN	4.14	33.6	-	-0.73
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-15	XGN	-0.21	-10.03	4.83
2026-10-16	XGN	-0.21	-10.03	4.83
2026-10-19	XGN	-0.21	-10.03	4.83
2026-10-20	XGN	-0.42	-10.03	4.83
2026-10-21	XGN	-0.42	-10.03	4.83
2026-10-22	XGN	-0.42	-10.03	4.89
2026-10-23	XGN	-0.41	-10.03	4.89
2026-10-26	XGN	-0.41	-11.68	4.89
2026-10-27	XGN	-0.41	-11.68	4.68
2026-10-28	XGN	-0.41	-11.68	4.68
2026-10-29	XGN	-0.41	-11.68	4.68
2026-10-30	XGN	-0.41	-11.68	4.68
2026-11-02	XGN	-0.41	-10.00	4.68
2026-11-03	XGN	-0.41	-10.00	4.68
2026-11-05	XGN	-0.41	-10.00	4.68
2026-11-06	XGN	-0.41	-10.00	4.68
2026-11-09	XGN	-0.41	-8.78	4.68
2026-11-10	XGN	-0.41	-8.78	4.68
2026-11-11	XGN	-0.37	-8.78	5.05
2026-11-12	XGN	0.34	-8.78	5.05
2026-11-13	XGN	0.34	-8.78	4.80
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.25

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.17

Insider Transactions

0.34

Institutional Transactions

-8.78

Beta

2.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

70.5

Max Drawdown 5-Year %

-89.4

Target Price

9.43

P/E

Forward P/E

PEG

P/S

1.46

P/B

7.62

P/Free Cash Flow

EPS

-0.75

Average EPS Est. Cur. Y

-0.73

EPS Next Y. (Est.)

-0.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-25.14

Relative Volume

8.58

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.11

EBIT Estimation

◆ XGN Healthcare

$4.13

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

7/25

Volume

3/15

Valuation

12/20

TP/AR

4/10

Options

7/10

RSI

28.8

Range 1M

6.4%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

18/25

Growth

17/30

Estimates

3/20

Inst/Vol

3/15

Options

7/10

EPS Yr

22.3%

EPS NY

24.3%

52W%

24%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +128.3% upside

Quality

5/30

Valuation

16/30

Growth

16/25

Stability

3/10

LT Trend

4/5

Upside

+128.3%

Quality

XGN — P/E HistoricalDiagnostics & Research

Exagen Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 216

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

XGN

Latest News

—

Caricamento notizie per XGN…

stock quote shares XGN – Exagen Inc. Stock Price stock today

news today XGN – Exagen Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch XGN – Exagen Inc. yahoo finance google finance

stock history XGN – Exagen Inc. invest stock market

stock prices XGN premarket after hours

ticker XGN fair value insiders trading

VCYT – Veracyte Inc.

VCYT — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

12.07

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

-0.03

EPS Last/This Y

0.16

EPS This/Next Y

-0.33

Price

24.32

Target Price

44.6

Analyst Recom

1.46

Performance Q

-42.18

Upside

-17.2%

Beta

1.99

Ticker: VCYT

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-15	VCYT	44.36	0.90	0.08	6739
2026-10-16	VCYT	43.16	0.90	207.00	6718
2026-10-19	VCYT	43.8	0.62	0.08	5435
2026-10-20	VCYT	44.83	0.62	3.00	5444
2026-10-21	VCYT	46.25	0.65	0.50	5540
2026-10-22	VCYT	46.11	0.65	7.79	5552
2026-10-23	VCYT	47.98	0.76	0.04	5994
2026-10-26	VCYT	48.22	0.77	0.27	5982
2026-10-27	VCYT	50.49	0.76	0.26	5983
2026-10-28	VCYT	50.31	0.81	0.46	5846
2026-10-29	VCYT	52.2	0.80	0.30	5854
2026-10-30	VCYT	49.99	0.81	0.88	5843
2026-11-02	VCYT	49.07	0.81	0.04	5826
2026-11-03	VCYT	50.3	0.80	1.21	5847
2026-11-04	VCYT	52.52	0.69	1.54	5489
2026-11-05	VCYT	23.98	0.64	0.33	6465
2026-11-06	VCYT	24.15	0.77	1.74	6547
2026-11-09	VCYT	25.93	0.70	0.13	6263
2026-11-10	VCYT	24.02	0.56	0.20	6936
2026-11-11	VCYT	25.09	0.56	0.15	6912
2026-11-12	VCYT	24.61	0.56	22.51	6918
2026-11-13	VCYT	24.32	0.41	0.87	6256
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-15	VCYT	44.37	-19.5	-9.4	1.91
2026-10-16	VCYT	43.16	-19.5	-16.0	1.91
2026-10-19	VCYT	43.78	-19.5	-11.0	1.91
2026-10-20	VCYT	43.78	-19.5	-11.0	1.91
2026-10-21	VCYT	44.81	-19.5	-8.1	1.91
2026-10-22	VCYT	46.08	-19.5	-13.1	1.91
2026-10-23	VCYT	47.92	-19.5	-8.1	1.91
2026-10-26	VCYT	48.24	-19.5	-12.0	1.91
2026-10-27	VCYT	50.42	-19.7	-7.4	1.91
2026-10-28	VCYT	50.30	-19.7	-7.8	1.91
2026-10-29	VCYT	52.17	-19.7	-8.5	1.91
2026-10-30	VCYT	49.99	-19.7	-17.6	1.91
2026-11-02	VCYT	49.06	-19.7	-14.8	1.91
2026-11-03	VCYT	50.29	-19.7	-12.1	1.91
2026-11-04	VCYT	52.52	-19.7	-7.7	1.91
2026-11-05	VCYT	23.92	-19.7	-75.6	1.91
2026-11-06	VCYT	24.00	-19.7	4.0	1.91
2026-11-09	VCYT	25.90	-19.7	-6.0	1.91
2026-11-10	VCYT	24.06	-24.1	-23.8	1.95
2026-11-11	VCYT	25.09	-24.7	-9.6	1.95
2026-11-12	VCYT	24.61	-24.7	-17.3	1.95
2026-11-13	VCYT	24.32	-27.9	-16.5	1.94
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-15	VCYT	-13.90	3.56	12.90
2026-10-16	VCYT	-13.90	3.56	12.90
2026-10-19	VCYT	-13.90	2.78	12.90
2026-10-20	VCYT	-13.90	2.78	12.90
2026-10-21	VCYT	-14.00	2.78	12.90
2026-10-22	VCYT	-14.00	2.78	12.90
2026-10-23	VCYT	-14.00	2.78	12.90
2026-10-26	VCYT	-14.00	2.80	12.90
2026-10-27	VCYT	-14.00	2.80	12.44
2026-10-28	VCYT	-14.00	2.80	12.44
2026-10-29	VCYT	-15.47	2.80	12.44
2026-10-30	VCYT	-15.47	2.80	12.44
2026-11-02	VCYT	-15.47	3.13	12.44
2026-11-03	VCYT	-15.47	3.13	12.44
2026-11-05	VCYT	-15.47	3.13	12.44
2026-11-06	VCYT	-15.47	3.13	12.44
2026-11-09	VCYT	-14.93	2.97	12.40
2026-11-10	VCYT	-14.93	2.97	12.40
2026-11-11	VCYT	-14.93	2.97	12.07
2026-11-12	VCYT	-14.93	2.97	12.07
2026-11-13	VCYT	-14.93	2.97	12.07
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.38

Avg. EPS Est. Current Quarter

0.38

Avg. EPS Est. Next Quarter

0.35

Insider Transactions

-14.93

Institutional Transactions

2.97

Beta

1.99

Average Sales Estimate Current Quarter

150

Average Sales Estimate Next Quarter

148

Fair Value

43.25

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

60.1

Max Drawdown 5-Year %

-68.9

Target Price

44.6

P/E

15.7

Forward P/E

15.53

PEG

P/S

3.37

P/B

1.37

P/Free Cash Flow

12.12

EPS

1.55

Average EPS Est. Cur. Y

1.94

EPS Next Y. (Est.)

1.61

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

21.8

Relative Volume

1.13

Return on Equity vs Sector %

-17.6

Return on Equity vs Industry %

-2.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

-16.5

◆ VCYT Healthcare

$24.33

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

16/20

Pullback

13/25

Volume

1/15

Valuation

20/20

TP/AR

2/10

Options

6/10

RSI

28.1

Range 1M

8.1%

Sup Dist

1.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

10/25

Growth

16/30

Estimates

4/20

Inst/Vol

6/15

Options

6/10

EPS Yr

7.6%

EPS NY

-18.2%

52W%

6.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +33% upside

Quality

8/30

Valuation

18/30

Growth

9/25

Stability

9/10

LT Trend

3/5

Upside

+33%

Quality

MoS

78%

VCYT — P/E HistoricalBiotechnology

Veracyte, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 755

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT

Latest News

—

Caricamento notizie per VCYT…

stock quote shares VCYT – Veracyte Inc. Stock Price stock today

news today VCYT – Veracyte Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VCYT – Veracyte Inc. yahoo finance google finance

stock history VCYT – Veracyte Inc. invest stock market

stock prices VCYT premarket after hours

ticker VCYT fair value insiders trading

CSTL – Castle Biosciences Inc.

CSTL — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

6.98

Margin Of Safety %

-23

Put/Call OI Ratio

0.91

EPS Next Q Diff

-0.18

EPS Last/This Y

-0.69

EPS This/Next Y

0.03

Price

33.78

Target Price

48.2

Analyst Recom

1.1

Performance Q

12.82

Upside

-179.8%

Beta

0.96

Ticker: CSTL

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-15	CSTL	33.8	0.22	999.99	477
2026-10-16	CSTL	31.98	0.22	0.00	477
2026-10-19	CSTL	32.17	0.38	0.50	155
2026-10-20	CSTL	33.06	0.38	0.50	155
2026-10-21	CSTL	34.38	0.39	0.00	157
2026-10-22	CSTL	33.17	0.39	0.00	157
2026-10-23	CSTL	33.14	0.39	0.00	157
2026-10-26	CSTL	33.25	0.39	0.00	157
2026-10-27	CSTL	34.5	0.39	999.99	158
2026-10-28	CSTL	36.63	0.39	0.50	159
2026-10-29	CSTL	38.52	0.40	0.00	164
2026-10-30	CSTL	37.06	0.35	0.00	180
2026-11-02	CSTL	34.89	0.35	4.00	181
2026-11-03	CSTL	35.22	0.35	2.00	181
2026-11-04	CSTL	35.8	0.38	0.60	186
2026-11-05	CSTL	34.1	0.40	1.00	190
2026-11-06	CSTL	32.51	0.90	0.25	1690
2026-11-09	CSTL	34.44	0.91	999.99	1688
2026-11-10	CSTL	34.36	0.91	999.99	1688
2026-11-11	CSTL	33.96	0.91	999.99	1688
2026-11-12	CSTL	34.49	0.91	1.00	1688
2026-11-13	CSTL	33.77	0.91	1.00	1688
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-15	CSTL	33.79	-100.0	-	-1.27
2026-10-16	CSTL	32.03	-100.0	-	-1.26
2026-10-19	CSTL	32.18	-100.0	-	-1.26
2026-10-20	CSTL	32.18	-100.0	-	-1.26
2026-10-21	CSTL	33.12	-100.0	-	-1.26
2026-10-22	CSTL	33.09	-100.0	-	-1.26
2026-10-23	CSTL	33.18	-100.0	-	-1.26
2026-10-26	CSTL	33.26	-100.0	-	-1.26
2026-10-27	CSTL	34.42	-100.0	-	-1.26
2026-10-28	CSTL	36.67	-100.0	-	-1.26
2026-10-29	CSTL	38.51	-100.0	-	-1.26
2026-10-30	CSTL	37.14	-100.0	-	-1.26
2026-11-02	CSTL	34.93	-100.0	-	-1.26
2026-11-03	CSTL	35.16	-100.0	-	-1.26
2026-11-04	CSTL	35.81	-100.0	-	-1.26
2026-11-05	CSTL	34.09	-100.0	-	-1.26
2026-11-06	CSTL	32.49	-100.0	-	-1.25
2026-11-09	CSTL	34.44	-100.0	-	-1.25
2026-11-10	CSTL	34.36	-100.0	-	-1.25
2026-11-11	CSTL	33.96	-100.0	-	-1.25
2026-11-12	CSTL	34.46	-100.0	-	-1.25
2026-11-13	CSTL	33.78	-81.2	-	-0.83
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-15	CSTL	-34.67	-0.98	6.68
2026-10-16	CSTL	-34.67	-0.98	6.68
2026-10-19	CSTL	-34.67	-0.35	6.68
2026-10-20	CSTL	-34.78	-0.35	6.68
2026-10-21	CSTL	-34.78	-0.35	6.68
2026-10-22	CSTL	-35.78	-0.35	6.68
2026-10-23	CSTL	-35.78	-0.35	6.68
2026-10-26	CSTL	-35.49	-0.61	6.68
2026-10-27	CSTL	-35.50	-0.61	6.74
2026-10-28	CSTL	-35.50	-0.61	6.74
2026-10-29	CSTL	-35.72	-0.61	6.74
2026-10-30	CSTL	-35.72	-0.61	6.74
2026-11-02	CSTL	-36.16	-0.66	6.74
2026-11-03	CSTL	-36.16	-0.66	6.74
2026-11-05	CSTL	-37.11	-0.66	6.74
2026-11-06	CSTL	-37.11	-0.66	6.74
2026-11-09	CSTL	-36.91	-5.75	6.68
2026-11-10	CSTL	-36.91	-5.75	6.68
2026-11-11	CSTL	-36.91	-5.75	6.98
2026-11-12	CSTL	-36.27	-5.75	6.98
2026-11-13	CSTL	-36.67	-5.75	6.98
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.31

Insider Transactions

-36.67

Institutional Transactions

-5.75

Beta

0.96

Average Sales Estimate Current Quarter

100

Average Sales Estimate Next Quarter

101

Fair Value

25.93

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

38.2

Max Drawdown 5-Year %

-78.5

Target Price

48.2

P/E

Forward P/E

PEG

P/S

2.76

P/B

2.17

P/Free Cash Flow

262.97

EPS

-0.77

Average EPS Est. Cur. Y

-0.83

EPS Next Y. (Est.)

-0.8

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6.1

Relative Volume

0.91

Return on Equity vs Sector %

-31.2

Return on Equity vs Industry %

-16.2

EPS 1 7Days Diff

0.4

EPS 1 30Days Diff

0.44

EBIT Estimation

◆ CSTL Healthcare

$33.79

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

23/25

Volume

7/15

Valuation

12/20

TP/AR

3/10

Options

3/10

RSI

47.8

Range 1M

31.9%

Sup Dist

1.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

17/30

Estimates

4/20

Inst/Vol

3/15

Options

4/10

EPS Yr

-3%

EPS NY

27%

52W%

61%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +3.1% upside

Quality

6/30

Valuation

4/30

Growth

13/25

Stability

8/10

LT Trend

0/5

Upside

+3.1%

Quality

MoS

-23%

CSTL — P/E HistoricalDiagnostics & Research

Castle Biosciences, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 1048

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CSTL

Latest News

—

Caricamento notizie per CSTL…

stock quote shares CSTL – Castle Biosciences Inc. Stock Price stock today

news today CSTL – Castle Biosciences Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch CSTL – Castle Biosciences Inc. yahoo finance google finance

stock history CSTL – Castle Biosciences Inc. invest stock market

stock prices CSTL premarket after hours

ticker CSTL fair value insiders trading

RVTY – Revvity Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RVTY

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

XGN – Exagen Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: XGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y